JPMorgan Chase & Co. Sells 108,996 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)

JPMorgan Chase & Co. decreased its position in Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) by 12.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 775,871 shares of the company's stock after selling 108,996 shares during the quarter. JPMorgan Chase & Co. owned about 2.30% of Sera Prognostics worth $6,316,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Barclays PLC increased its position in shares of Sera Prognostics by 321.6% in the third quarter. Barclays PLC now owns 39,450 shares of the company's stock worth $308,000 after acquiring an additional 30,093 shares in the last quarter. Geode Capital Management LLC lifted its stake in Sera Prognostics by 8.9% in the third quarter. Geode Capital Management LLC now owns 586,837 shares of the company's stock valued at $4,578,000 after acquiring an additional 47,969 shares during the last quarter. State Street Corp lifted its stake in Sera Prognostics by 8.8% in the third quarter. State Street Corp now owns 425,093 shares of the company's stock valued at $3,316,000 after acquiring an additional 34,479 shares during the last quarter. Sanders Morris Harris LLC lifted its stake in Sera Prognostics by 165.7% in the fourth quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company's stock valued at $725,000 after acquiring an additional 56,500 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Sera Prognostics by 5.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 81,228 shares of the company's stock worth $661,000 after buying an additional 4,115 shares during the last quarter. Institutional investors and hedge funds own 54.64% of the company's stock.

Sera Prognostics Stock Performance

Shares of Sera Prognostics stock traded up $0.17 on Wednesday, reaching $3.65. The stock had a trading volume of 3,883 shares, compared to its average volume of 130,437. The business's 50-day moving average price is $3.82 and its two-hundred day moving average price is $5.89. Sera Prognostics, Inc. has a fifty-two week low of $2.99 and a fifty-two week high of $12.36. The stock has a market cap of $137.47 million, a P/E ratio of -3.69 and a beta of 0.96.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings data on Wednesday, March 19th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.02). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million. During the same period last year, the firm earned ($0.25) EPS. As a group, equities analysts forecast that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

Sera Prognostics Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.